Adrenocortical carcinoma as a manifestation of Birt–Hogg–Dubé syndrome
Endocrine-Related Cancer · 01.03.2026 · 33 (3)
DOI: 10.1530/erc-25-0285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 16.03.2026. Verfasst von Katherine I Wolf und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Metabolism, Endocrinology, & Diabetes, Endocrine Oncology Program, Michigan Medicine, Ann Arbor, Michiga…. Hauptthemen laut MEDLINE: Birt-Hogg-Dube Syndrome, Adrenocortical Carcinoma, Adrenal Cortex Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Birt–Hogg–Dubé syndrome (BHDS) is characterized by fibrofolliculomas, trichodiscomas, renal tumors, lung cysts, and spontaneous pneumothoraces. Other than renal cell carcinoma, no cancers have been confirmed as part of the BHDS tumor spectrum. Here, we set out to uncover if adrenocortical carcinoma (ACC) is associated with BHDS. A retrospective review at a single tertiary care center between 2010 and 2024 was performed using search terms describing the clinical manifestations of BHDS, adrenal tumors, and iterations thereof. The initial review identified 1,010 patients with ACC. Of these patients, 466 were evaluated by a genetic counselor, and 346 underwent genetic testing—seven of which were found to have either characteristic clinical features of BHDS or a confirmed diagnosis. The literature review over the same time period demonstrated five additional cases of malignant adrenal tumors in patients with BHDS. We observed BHDS, confirmed by a pathogenic FLCN variant in 0.7% of all ACC patients, or 1.5% of patients evaluated by a genetic counselor and 2.0% of all patients who underwent genetic testing. Testing for FLCN pathogenic variants should be considered during routine genetic evaluation of patients with ACC, and special attention should be paid to adrenal tumors in BHDS patients during surveillance for renal neoplasms as more than 50% of patients in this series developed metastatic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Metabolism, Endocrinology, & Diabetes, Endocrine Oncology Program, Michigan Medicine, Ann Arbor, Michigan, USA.
- Department of Internal Medicine, Division of Genetic Medicine, Michigan Medicine, Ann Arbor, Michigan, USA.
- Department of Pathology, Michigan Medicine, Ann Arbor, Michigan, USA.
- Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Endocrine Neoplasia & Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Katherine I Wolf
Förderung
- NIDDK NIH HHS
Zitieren
APA
Wolf, K. I., Osborne, J., Lerario, A. M., Vo, J. N., Hamidi, O., Habra, M. A., Hammer, G., & Else, T. (2026). Adrenocortical carcinoma as a manifestation of Birt–Hogg–Dubé syndrome. Endocrine-Related Cancer, 33(3). https://doi.org/10.1530/erc-25-0285
Vancouver
Wolf KI, Osborne J, Lerario AM, Vo JN, Hamidi O, Habra MA, et al. Adrenocortical carcinoma as a manifestation of Birt–Hogg–Dubé syndrome. Endocrine-Related Cancer. 2026;33(3). doi:10.1530/erc-25-0285
BibTeX
@article{Wolf2026,
author = {Wolf, Katherine I and Osborne, Jenae and Lerario, Antonio M and Vo, Josh N and Hamidi, Oksana and Habra, Mouhammed Amir and Hammer, Gary and Else, Tobias},
title = {Adrenocortical carcinoma as a manifestation of Birt–Hogg–Dubé syndrome},
journal = {Endocrine-Related Cancer},
year = {2026},
volume = {33},
number = {3},
doi = {10.1530/erc-25-0285}
}
EUVIMED